Status:
UNKNOWN
Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Inflammatory Bowel Disease
Eligibility:
All Genders
18-90 years
Phase:
EARLY_PHASE1
Brief Summary
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease. And...
Detailed Description
Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis (UC) and Crohn's disease(CD).CD is an autoimmune condition resulting in chronic gut inflammation that can be co...
Eligibility Criteria
Inclusion
- suspected or confirmed untreated inflammatory bowel disease patients;
- 18F-FDG PET/CT within two weeks;
- signed written consent.
Exclusion
- pregnancy;
- breastfeeding;
- known allergy against FAPI
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04507932
Start Date
August 1 2020
End Date
December 1 2022
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730